<DOC>
	<DOCNO>NCT00360854</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Radiation therapy use high-energy x-ray kill tumor cell . Giving erlotinib together radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose erlotinib give alone together radiation therapy treat young patient refractory relapse malignant brain tumor newly diagnose brain stem glioma .</brief_summary>
	<brief_title>Erlotinib Alone Combination With Radiation Therapy Treating Young Patients With Refractory Relapsed Malignant Brain Tumors Newly Diagnosed Brain Stem Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Establish maximum tolerate dose single-agent erlotinib hydrochloride pediatric patient refractory relapse malignant brain tumor combination radiotherapy pediatric patient newly diagnose brain stem glioma . Secondary - Determine dose-limiting toxicity regimens . - Define safety profile regimen . - Characterize pharmacokinetic behavior erlotinib hydrochloride patient . - Evaluate efficacy regimen . - Correlate expression mutation epidermal growth factor receptor treatment response . OUTLINE : This multicenter , nonrandomized , open-label , dose-escalation study erlotinib hydrochloride . Patients assign 1 2 treatment group accord disease . - Group 1 ( refractory relapse malignant brain tumor ) : Patients receive oral erlotinib hydrochloride daily day 1-21 . Treatment repeat every 21 day absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos erlotinib hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity ( DLT ) . - Group 2 ( newly diagnose brain stem glioma ) : Patients receive oral erlotinib hydrochloride daily day 1-21 . Treatment repeat every 21 day absence unacceptable toxicity disease progression . Beginning day 1 , patient also undergo radiotherapy 5 day week 6 week . Cohorts 1-2 patient receive escalate dos erlotinib hydrochloride MTD determine . The MTD define dose result 25 % patient experience DLT 6 week . Blood collect pharmacokinetic assessment pharmacogenetic genotyping analysis enzyme polymorphism . Tumor tissue may assess epidermal growth factor receptor mutation . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 48 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Histologically cytologically confirm malignant brain tumor Refractory firstline therapy relapse conventional therapy No effective conventional therapy exist Histologically confirm brain stem glioma Newly diagnose disease No pilocytic glioma Measurable evaluable disease PATIENT CHARACTERISTICS : WHO performance status 02 OR Lansky play scale 50100 % Patients motor paresis due disease eligible Neurological deficit must stable ≥ 1 week Life expectancy ≥ 8 week Absolute neutrophil count &gt; 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8 g/dL AST/ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Creatinine &lt; 1.5 time ULN OR creatinine clearance ≥ 70 mL/min No serious , uncontrolled illness No active infection No organ toxicity ≥ grade 2 except alopecia neurological symptom due disease Must able take oral medication Patients newly diagnose brain stem glioma difficulty swallowing may eligible Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No evidence pulmonary dysfunction preexist lung disease No myocardial infarction within past year No severe cardiac pathology No significant ophthalmologic abnormality include , limited , follow : Severe dry eye syndrome Keratoconjunctivitis sicca Sjögren 's syndrome Severe exposure keratitis Any disorder likely increase risk corneal epithelial lesion PRIOR CONCURRENT THERAPY : More 4 week since prior chemotherapy ( 6 week nitrosoureas ) More 6 week since prior radiotherapy No concurrent warfarin No concurrent anticancer investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>untreated childhood brain stem glioma</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>childhood grade I meningioma</keyword>
	<keyword>childhood grade II meningioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
	<keyword>recurrent childhood subependymal giant cell astrocytoma</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
</DOC>